Logo image
Back
Proton Therapy for Head and Neck Adenoid Cystic Carcinoma: A Multi-institutional Review
Journal article - Review   Open access   Peer reviewed

Proton Therapy for Head and Neck Adenoid Cystic Carcinoma: A Multi-institutional Review

Lisa A. McGee, Astha Rohit, Matthew Buras, Gopal Bajaj, John H. Chang, Noah S. Kalman, Ryan Grover, Adil Akthar, Adam J. Kole, Mark McDonald, …
International journal of particle therapy, v 20, 101320
01 Jun 2026
DOI: https://doi.org/10.1016/j.ijpt.2026.101320
PMID: 42205853
url
https://doi.org/10.1016/j.ijpt.2026.101320View
Published, Version of Record (VoR) Open CC BY V4.0

Abstract

Adenoid cystic carcinoma Proton beam therapy Salivary gland cancer
To evaluate efficacy and toxicity (CTCAE v4.0) outcomes in patients with adenoid cystic carcinoma (ACC) treated with proton beam therapy (PBT). From 2012 through 2023, 79 patients with non-metastatic ACC were treated with PBT and enrolled on the Proton Collaborative Group (PCG) registry. Kaplan-Meier analyses quantified locoregional control (LRC), disease-free survival (DFS), and overall survival (OS). ACC patients receiving reirradiation with PBT were excluded from this analysis. Median follow-up was 3 years (0.01–6.72). Twenty-six patients were unable to undergo surgery and received definitive PBT versus postoperative PBT (n=53). Median postoperative PBT dose was 66 GyE and 70 GyE for definitive patients treated with conventional fractionation. Most patients had localized disease (n=75); few had nodal metastases (n=4). 62% were locally advanced (T3-T4) at the time of PBT treatment. 3-year Locoregional control (LRC) for all patients was 98% [95% CI (94.3, 100)]. Advanced T-staging, positive margins and definitive-intent PBT were not associated with worsened LRC. 3-year Progression free survival (PFS) was 80.5% (70.6, 91.7). Patients receiving definitive intent PBT had lower but nonsignificant PFS (73.3% vs. 83.8%, p-0.075). Advanced T-staging and positive margins did not have worsened PFS. Overall survival at 3 years was 89.2% (81.4, 97.8). Acute grade 3 toxicities occurred in 16 patients, the most common included the following: mucositis (n=5), oral pain (n=3), and dermatitis (n=5). Late grade 3 toxicity (n=2) included middle ear inflammation (n=1) and skin ulceration (n=1). There were no grade 4+ toxicities. PBT appears to be highly efficacious in providing LRC for patients with ACC including those patients treated with definitive intent. PBT toxicity was acceptable. Longer follow-up is needed.

Metrics

1 Record Views

Details

Logo image